AMP® SCZ is Seeking Phase 2 Ready Compounds with Relevance to Clinical High Risk for Psychosis

We're now on Instagram! Follow us @NIMHgov REQUEST FOR INFORMATION Request for Information (RFI) on Phase 2 Ready Compounds for use in Accelerating Medicines® Schizophrenia (SCZ) Program Proof of Principle Trials in Clinical High Risk for Psychosis (CHR) Respond by February 3, 2023! Respond to the RFI The National Institute of Mental Health is delighted to be a partner on the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). The Foundation for the National Institutes of Health (NIH) is requesting information on Phase 2-ready compounds with a compelling biological hypothesis to address biological or clinical outcomes in the earliest stages of schizophrenia. This high-level overview is requested to inform on the selection of compounds for use in a biomarker focused proof of principle trial(s). The AMP SCZ project team looks forward to receiving your proposals and submissions by February 3, 2023!

NIMH Science News Questions? Contact NIMH! Director's Messages SUBSCRIBER SERVICES: Manage Preferences  |  Unsubscribe  |  Help

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Mental Health · 6001 Executive Boulevard · Bethesda, MD 20892-9663 · 1-866-615-6464